European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. NAVN
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
Gilead Sciences (NASDAQ: GILD) Delayed: 124.87 --0 (-0%)
Previous Close $124.87    52 Week High $108.63 
Open $124.87    52 Week Low $71.39 
Day High $124.87    P/E 68.99 
Day Low $124.87    EPS $1.81 
Volume 8,363